Jupiter Neurosciences

Q1 FY2026 EarningsQ2 FY2026 results missed revenue consensus significantly, reporting $24,245 vs. $313,000 expected, as the Nugevia product line scale-up remains in early stages. Normalized Net Loss of -$2.27M was narrower than the -$1.89M consensus due to a $549k non-cash gain from the fair value adjustment of convertible notes. However, a 'going concern' warning persists as the company executed a 1-for-75 reverse stock split in August 2026 to maintain its Nasdaq listing amid severe liquidity constraints.